Keyword: Teva Pharmaceutical
Teva will produce its new migraine drug at a plant in Israel and more news of note.
Teva is riding high after a strong launch for Austedo. But is "tenfold" patient growth in one of its indications possible? Analysts aren't so sure.
A look at third-quarter numbers shows many top players are rolling right along—though some Big Pharmas weren't so lucky.
A number of high-dollar settlements could be coming as drugmakers look to bail on opioid suits. Will they top the largest deals in the last two years?
Teva will begin producing chemo drug vincristine in the U.S. but has resisted the idea that its withdrawal from the market led to a shortage.
With an eye-popping $23 billion deal on the table to settle its opioid suits, Teva is setting aside even more funds to cover its possible liabilities.
With two oncology blockbuster already facing U.S. biosims, Roche is facing a tough road ahead. Now, a third Roche cancer med is in the firing line.
Paul Campanelli was a steady hand after years of turmoil at Endo. Now, with the drugmaker facing rough seas ahead, it will look for a new leader.
After 14 years of litigation, a slew of drugmakers are finally settling a protracted battle over claims they defrauded Illinois' Medicaid program.